Zacks Investment Research on MSN20h
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline UpdateNovo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...
Public-facing conversation regarding breast cancer is grounded in historical gender bias and is an example of the disparities in healthcare that women continue to face.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback